7DC6D598-8506-4680-81DF-C1D0F1B5C27D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 35.34822601839684
- age_years
- 50
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.518
- G2M_CHECKPOINT+0.495
- MYC_TARGETS_V1+0.464
- MYC_TARGETS_V2+0.419
- MITOTIC_SPINDLE+0.306
- DNA_REPAIR+0.300
- OXIDATIVE_PHOSPHORYLATION+0.279
- HEDGEHOG_SIGNALING+0.212
- PROTEIN_SECRETION+0.195
- UNFOLDED_PROTEIN_RESPONSE+0.176
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.468
- IL6_JAK_STAT3_SIGNALING-0.459
- INFLAMMATORY_RESPONSE-0.444
- INTERFERON_GAMMA_RESPONSE-0.439
- ALLOGRAFT_REJECTION-0.435
- COAGULATION-0.431
- INTERFERON_ALPHA_RESPONSE-0.409
- ANGIOGENESIS-0.392
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.382
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598206 | fetal | fetal | 0.932 |
| 2 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.927 |
| 3 | BS_1HQ76V6D | Embryonal tumors | — | 0.923 |
| 4 | SRR1797283 | — | cohortSC | 0.920 |
| 5 | ERR2598195 | fetal | fetal | 0.920 |
| 6 | SRR13780247 | — | cohortMD1 | 0.913 |
| 7 | 20120209.TNBC | — | E | 0.910 |
| 8 | BS_8QB4S4VA | Embryonal tumors | — | 0.909 |
| 9 | TCGA-78-7155-01A-11R-2039-07 | — | cohortMD1 | 0.908 |
| 10 | CA366342-0949-4941-8AE6-984BAF032886 | — | — | 0.908 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.518 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.495 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.464 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.419 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.306 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.279 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.212 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.195 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.176 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.132 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.132 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.123 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.084 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.054 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| PEROXISOME | 0.029 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.015 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.011 | Inavolisib | — uncovered |